International Journal of Drug Delivery Technology
Volume 14, Issue 1

Development and Evaluation of Riluzole Loaded PLGA Nanoparticles for Improved Permeability across BBB

Jayavasavi G, Sathesh K Sukumaran*

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India. 

Received: 15th September, 2023; Revised: 01st January, 2024; Accepted: 17th February, 2024; Available Online: 25th March, 2024

ABSTRACT

Blood-brain barrier is a physiological barrier that prevents drugs from reaching the brain or being bioavailable for treating brain disorders. Degenerative diseases like amyotrophic lateral sclerosis (ALS) seriously impact our daily lives. The Food and Drug Administration (FDA) approved this drug to treat ALS as a chemical derivative of 2- amino-6 [tri-fluoro-methoxy] benzo-thiazole. In order to improve the drug’s therapeutic efficacy, poly-(lactic-co-glycolic acid) nanoparticles (PLGA) were loaded with riluzole and deposited using emulsifying solvent deposition. A design expert software program was used to optimize formulation parameters, including polymer concentration, surfactant concentration, and stirring speed, based on the particle size, zeta potential, and entrapment efficiency responses. Three formulations were taken forward for further study based on the results of 20 trials. Compared to differential scanning calorimetry and fourier transform infrared spectroscopy (FTIR) studies performed beforehand, there were no significant interactions between RZL and the excipients. Nanoparticles prepared with scanning electron microscopy had a smooth surface and a spherical shape. The particle size distribution ranged from 184 ± 74 nm to a maximum of 204.5 ± 71. As a consequence, the particle size distribution is relatively narrow, with lower polymer concentrations, and is ideal for drug delivery. A range of -17.3 to -18.2mV was found for the zeta potential of the nanoparticles. The encapsulation efficiency ranged from 42.61 ± 3.61 to 60.02 ± 1.94%, forming 1:1 to 1:4 drug: Polymer ratios, respectively. Over a period of 22 to 26 hours, the RLZ was continuously released from the nanoparticles. A loading dose may be built by 24% of the drug being released within 3 hours of administration.

Keywords: Polymeric nanoparticles, Riluzole, Blood-brain barrier, Amyotrophic lateral sclerosis, Neurodegenerative disorder, Entrapment efficiency, In-vitro drug release.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.06

How to cite this article: Jayavasavi, Sukumaran SK. Development and Evaluation of Riluzole Loaded PLGA Nanoparticles for Improved Permeability across BBB. International Journal of Drug Delivery Technology. 2024;14(1):33-37.

REFERENCES

  1. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008; 57: 178–201.
  2. Cheah BC, Vucic S, Krishnan AV, Kiernan MCRiluzole, NeuroprotectionAnd Amyotrophic Lateral Sclerosis. Curr Med Chem. 2010; 17:1942–1959.
  3. Bellingham A Review of the Neural Mechanisms of Action and Clinical Efficiency Of Riluzole In Treating Amyotrophic Lateral sclerosis: What Have We Learnt In The Past Decade? CNS NeurosciTher. 2011; 17:4–31.
  4. Heffernan C, Jenkinson C, Holmes T .Nutritional Management in MND/ALS Patients: An Evidence Based Amyotrophic Lateral Sclerosis. 2004; 5 (2):72–78.
  5. Samuel D, Blin O, Dusticier N, Nieoullon Effects of Riluzole (2-Amino-6-Trifluoromethoxy Benzothiozole) On Striatal Neuro-chemical markers in the rat, with Special Reference to the Dopamine, Choline, GABA and Glutamate Synaptosomal High Affinity Uptake Systems. Fundamclinpharmacol. 1992; 6:177–184.
  6. William J. Brammar. Ion Channel Facts book, Voltage-Gated Channels, Volume 4 in Facts book, Volume IV, 1999, Pages 768- https://doi.org/10.1016/B978-012184453-0/50018-4
  7. Michele Trotta, Francesca Debernardi, Otto Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique, International Journal of Pharmaceutics. 2003; 257: 153–160, doi:10.1016/S0378-5173(03)00135-2
  8. Ahn JH, Kim YP, Lee Optimization of microencapsulation of seed oil by response surface methodology. Food Chem. 2008;107:98–105.
  9. Das, S., Ng, W.K., Tan, R.B.H. Development and in vitro evaluations of a lipid nanoparticle formulation containing tretinoin. In: Tiddy, G., Tan, R.B.H. (Eds.), NanoFormulation. RSC Publishing, London, 2012; 38–52.
  10. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res. 2010;20:115–123.
  11. Das S, Kanaujia P, Kim S, Tan RBH. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf. B: Biointerfaces. 2011;88:483–489.
  12. Xavier Llorente, Gerard Esteruelas, Lorena Bonilla, Mariana Garnica Agudelo, Ingrid Filgaira, Daniel Lopez-Ramajo, Ruoyi C Gong, Concepció Soler, Marta Espina, Maria Luisa García, Joan Manils, Montserrat Pujol, Elena Sánchez-López, Riluzole- Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases, Int. J. Mol. Sci. 2023, 24, 8053